2nd COVID-19 Vaccine for Children Approved in India
Local media in India reported today that Bharat Biotech's Covaxin COVID-19 vaccine had been awarded by India's Subject Expert Committee Emergency Use Approval to vaccinate children between two and 18.
"The emergency use authorization, however, is subject to certain conditions. The developer of Covaxin will continue studying the vaccine per the approved clinical trial protocol", the drug regulator said.
Bharat Biotech's Covaxin (BBV152) is an inactivated COVID-19 vaccine that uses adjuvant Alhydroxiquim-II to boost immune response longer-lasting immunity.
The final approval will be given by the Drug Controller General of India (DGCI).
If approved, Covaxin will become the second vaccine to be cleared for use on children.
In August 2021, DCGI had granted emergency approval to the ZyCoV-D COVID-19 vaccine developed by the Zydus Cadillac group for use in adolescents 12 years old and above.
ZyCov-D was developed on a DNA platform using a non-replicating and non-integrating plasmid carrying the novel coronavirus gene. In addition, ZyCoV-D is a three-dose intradermal vaccine, which is applied using the PharmaJet® needle-free system, Tropis®, which can significantly reduce any side effects, says the Company.